Detalhe da pesquisa
1.
Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1.
Bioorg Chem
; 138: 106682, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37339563
2.
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
Bioorg Med Chem Lett
; 29(12): 1502-1506, 2019 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30992165
3.
Anticarcinogenic Effects of α-Mangostin: A Review.
Planta Med
; 83(3-04): 188-202, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27824406
4.
Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1.
RSC Med Chem
; 15(4): 1096-1108, 2024 Apr 24.
Artigo
Inglês
| MEDLINE | ID: mdl-38665824
5.
Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b).
J Med Chem
; 67(2): 816-837, 2024 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38181380
6.
Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.
J Med Chem
; 67(2): 1513-1532, 2024 Jan 25.
Artigo
Inglês
| MEDLINE | ID: mdl-38175809
7.
Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).
Mini Rev Med Chem
; 23(11): 1154-1166, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-35747976
8.
Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.
J Med Chem
; 66(1): 1027-1047, 2023 01 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36595482
9.
Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
J Med Chem
; 66(7): 4378-4416, 2023 04 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36951608
10.
Novel Benzimidazoles as Potent Small-Molecule Inhibitors and Degraders of V-Domain Ig Suppressor of T-Cell Activation (VISTA).
J Med Chem
; 66(17): 11881-11892, 2023 09 14.
Artigo
Inglês
| MEDLINE | ID: mdl-37594853
11.
Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors.
Eur J Med Chem
; 250: 115217, 2023 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36842272
12.
Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery.
Eur J Med Chem
; 258: 115607, 2023 Oct 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37413882
13.
Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold.
Eur J Med Chem
; 256: 115468, 2023 Aug 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37207535
14.
Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy.
J Med Chem
; 66(24): 16807-16827, 2023 12 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38109261
15.
Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro).
Eur J Med Chem
; 257: 115487, 2023 Sep 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37257212
16.
The development of small-molecule inhibitors targeting HPK1.
Eur J Med Chem
; 244: 114819, 2022 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36209628
17.
Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
J Med Chem
; 65(18): 11900-11912, 2022 09 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36083840
18.
Design, Synthesis, and Evaluation of PD-1/PD-L1 Antagonists Bearing a Benzamide Scaffold.
ACS Med Chem Lett
; 13(4): 586-592, 2022 Apr 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35450381
19.
Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
J Med Chem
; 65(11): 7746-7769, 2022 06 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35640078
20.
Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein-protein interaction.
RSC Adv
; 11(38): 23270-23279, 2021 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35479790